Hopital Purpan

Hopital Purpan’s neurology department is also conducting studies that address infection‑related complications, such as prosthetic joint infection and the prevention of surgical site infections. Researchers are evaluating the safety and effectiveness of different antimicrobial regimens, including narrow‑spectrum versus broad‑spectrum therapy for community‑acquired pneumonia in elderly patients.

• Prosthetic joint infection treatment strategies
• Surgical antibiotic prophylaxis comparison
• Antibiotic stewardship in pneumonia

The site currently supports a portfolio of 20 trials led by 24 investigators, reflecting a strong commitment to infection‑focused research alongside neurology.

Clinical investigations at Hopital Purpan include trials aimed at reducing the risk of recurrent vascular events, notably evaluating new oral anticoagulants for patients after an acute non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack. The studies focus on both efficacy in preventing further strokes and safety regarding bleeding risk.

• Stroke secondary prevention
• Anticoagulant efficacy versus placebo
• Bleeding safety assessments

With a multidisciplinary team, the department integrates cardiovascular research into its broader neurology program.

A series of trials at the site explore targeted immunomodulation for conditions such as polymyalgia rheumatica and rheumatoid arthritis. Participants receive novel biologics or small‑molecule inhibitors, and the studies measure sustained remission and structural joint protection.

• Biologic therapy in polymyalgia rheumatica
• Upadacitinib versus adalimumab in rheumatoid arthritis
• Glucocorticoid taper strategies

These immune‑focused projects complement the department’s neurological expertise, offering patients advanced treatment options.

Research on musculoskeletal health includes investigations of disease‑modifying agents for rheumatoid arthritis and studies on bone‑related outcomes in patients with inflammatory disorders. The trials assess both clinical signs and imaging markers of disease progression.

• Rituximab versus ocrelizumab in rheumatoid arthritis
• Structural progression prevention
• Long‑term safety of disease‑modifying drugs

The department’s collaboration with orthopedic specialists enhances the depth of musculoskeletal research.

The core of Hopital Purpan’s clinical portfolio centers on neurological disorders, ranging from acute stroke to chronic neurodegeneration. Ongoing studies evaluate novel agents for stroke recovery, disease‑modifying therapies for Alzheimer’s‑related mild cognitive impairment, and genetics‑guided treatments for Parkinson’s disease.

• Acute ischemic stroke therapeutic trials
• Mild cognitive impairment due to Alzheimer’s disease
• GBA‑related Parkinson’s disease interventions
• Multiple sclerosis comparative biologics

With 20 active trials, the neurology department remains a national hub for innovative brain‑focused research.

Investigators are addressing respiratory health by comparing antibiotic regimens for older adults hospitalized with community‑acquired pneumonia. The goal is to prove that a narrower spectrum drug can achieve similar cure rates while reducing side‑effects.

• Narrow‑spectrum versus broad‑spectrum antibiotics
• Day‑30 infection resolution outcomes
• Safety monitoring in elderly patients

These respiratory studies are integrated with the site’s broader infection and neurology research programs.

Several trials focus on viral infections, particularly HIV‑1. Participants are evaluating a switch to a new combination therapy to maintain viral suppression while improving tolerability. Safety and virologic efficacy are the primary endpoints.

• Switch to doravirine/islatravir regimen
• Viral load maintenance assessments
• Long‑term safety of novel antiretroviral combos

The virology work complements the department’s emphasis on immune‑mediated and neuro‑infectious conditions.

In addition to disease‑specific programs, Hopital Purpan conducts exploratory studies where the therapeutic focus is not yet defined. These projects often evaluate biomarkers, imaging tools, or novel delivery methods that could apply across multiple specialties.

• Biomarker discovery for neurodegeneration
• Advanced imaging techniques for disease monitoring
• Innovative drug delivery platforms

The site’s diverse investigator team of 24 professionals supports a dynamic research environment across all therapeutic areas.